In a significant step forward for the CBD industry, a coalition of CBD companies, known collectively as ONE HEMP, has taken the initiative to provide clarity on safe CBD consumption. This coalition’s primary goal is to engage with Congress and the Food and Drug Administration (FDA) to establish regulatory standards for CBD products. Recently, they submitted a groundbreaking study to U.S. officials, shedding light on safe upper intake limits for CBD.
Understanding the Study
The ONE HEMP study has determined that an upper intake limit of 70 milligrams of CBD per day is safe for healthy adults. Furthermore, it has revealed that an upper intake limit of 160 milligrams per day is safe for healthy adults who are not trying to conceive, pregnant, or lactating.
Addressing FDA Concerns
This comprehensive study was prompted by a Request for Information from House and Senate committees. It was specifically designed to address concerns raised by the FDA regarding the potential harm CBD might pose to liver and reproductive health.
Expert Insights
Dr. Rayetta G. Henderson Ph.D., senior managing scientist at ToxStrategies LLC, led the research team behind the study. She emphasized that the suggested upper intake limits for CBD closely align with recommendations put forth by leading regulatory bodies worldwide. These include Health Canada, Australia’s Therapeutic Goods Administration, and the U.K.’s Food Standards Agency.
Dr. Marcel Bonn-Miller Ph.D., chief scientific officer at Charlotte’s Web and part of the research team, emphasized the significance of this study for legislators and regulators. He believes it will play a pivotal role in determining manufacturing and labeling requirements for CBD supplement products.
Bon-Miller stated, “Implementing scientifically based safety limits is crucial to protecting consumers. This research is also aligned with ONE HEMP’s recommendations for accurate product labeling and, ultimately, holding CBD companies accountable for manufacturing and selling quality and safe products.”
ONE HEMP’s Mission
Charlotte’s Web, a founding member of ONE HEMP, has been at the forefront of advocating for stringent regulatory standards in the CBD industry. The coalition’s mission includes advocating for independent third-party testing and accurate product labeling.
Jared Stanley, co-founder and COO of Charlotte’s Web, highlighted the urgent need for clarity and stability in the CBD market. He emphasized that it’s high time for Congress to clarify the FDA’s mandate and definitively regulate CBD products as dietary supplements.
A Milestone for the CBD Industry
The peer-reviewed study submitted by ONE HEMP, published online on August 25 in the Regulatory Toxicology and Pharmacology journal, represents a significant milestone for the CBD industry. It provides a scientific basis for establishing safe CBD consumption limits and sets the stage for more transparent and precise regulations.
As the CBD industry matures and continues to gain popularity, clear guidelines and standards are essential to protect consumers and ensure the production of safe and reliable CBD products. The ONE HEMP study is a pivotal step towards achieving these goals and fostering a healthier and more accountable CBD industry.
Subscribe today to NECANN and stay updated with the latest cannabis news.
